<table>
<thead>
<tr>
<th>Title</th>
<th>KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Yoshikiyo, Kazunori</td>
</tr>
<tr>
<td>Citation</td>
<td>Kyoto University (京都大学)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2013-09-24</td>
</tr>
<tr>
<td>URL</td>
<td><a href="https://doi.org/10.14989/doctor.r12772">https://doi.org/10.14989/doctor.r12772</a></td>
</tr>
<tr>
<td>Type</td>
<td>Thesis or Dissertation</td>
</tr>
<tr>
<td>Textversion</td>
<td>ETD</td>
</tr>
<tr>
<td>Kyoto University</td>
<td></td>
</tr>
</tbody>
</table>

**Summary:**

KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents.
KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents

Kazunori Yoshikiyo, Katja Kratz, Kouji Hirota, Kana Nishihara, Minoru Takata, Hitoshi Kurumizaka, Satoshi Horimoto, Shunichi Takeda, and Josef Jiricny

Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan; Institute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland; Radiation Biology Center, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan; Laboratory of Structural Biology, Graduate School of Advanced Science and Engineering, Waseda University, Shinjuku-ku, Tokyo 162-8580, Japan; and *Department of Biology, Swiss Federal Institute of Technology, 8057 Zurich, Switzerland

Edited* by Martin Gellert, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, and approved November 5, 2010 (received for review July 29, 2010)

Fanconi anemia (FA) is a rare genetic disease characterized by congenital defects, bone marrow failure, chromosomal instability, and cancer susceptibility. One hallmark of cells from FA patients is hypersensitivity to interstrand cross-linking agents, such as the chemotherapeutics cisplatin and mitomycin C (MMC). We have recently characterized a FANC2/FANCI-associated nuclease, KIAA1018/FAN1, the depletion of which sensitzes human cells to these agents. However, as the down-regulation of FAN1 in human cells was mediated by siRNA and thus only transient, we were unable to study the long-term effects of FAN1 loss on chromosomal stability. We now describe the generation of chicken DT40 B cells, in which the FAN1 locus was disrupted by gene targeting. FAN1-null cells are highly sensitive to cisplatin and MMC, but not to ionizing or UV radiation, methyl methanesulfonate, or camptothecin. The cells do not display elevated sister chromatid exchange frequency, either sporadic or MMC-induced. Interestingly, MMC treatment causes chromosomal instability that is quantitatively, but not qualitatively, comparable to that seen in FA cells. This finding, coupled with evidence showing that DT40 cells deficient in both FAN1 and FANCC, or FAN1 and FANCJ, exhibited increased sensitivity to cisplatin compared with cells lacking only FAN1, suggests that, despite its association with FANC2/FANCI, FAN1 in DT40 cells participates in the processes of damage induced by interstrand cross-linking-generating agents also independently of the classical FA pathway.

KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents

Kazunori Yoshikiyo, Katja Kratz, Kouji Hirota, Kana Nishihara, Minoru Takata, Hitoshi Kurumizaka, Satoshi Horimoto, Shunichi Takeda, and Josef Jiricny

Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan; Institute of Molecular Cancer Research, University of Zurich, 8057 Zurich, Switzerland; Radiation Biology Center, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan; Laboratory of Structural Biology, Graduate School of Advanced Science and Engineering, Waseda University, Shinjuku-ku, Tokyo 162-8580, Japan; and *Department of Biology, Swiss Federal Institute of Technology, 8057 Zurich, Switzerland

Edited* by Martin Gellert, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, and approved November 5, 2010 (received for review July 29, 2010)

Fanconi anemia (FA) is a rare genetic disease characterized by congenital defects, bone marrow failure, chromosomal instability, and cancer susceptibility. One hallmark of cells from FA patients is hypersensitivity to interstrand cross-linking agents, such as the chemotherapeutics cisplatin and mitomycin C (MMC). We have recently characterized a FANC2/FANCI-associated nuclease, KIAA1018/FAN1, the depletion of which sensitizes human cells to these agents. However, as the down-regulation of FAN1 in human cells was mediated by siRNA and thus only transient, we were unable to study the long-term effects of FAN1 loss on chromosomal stability. We now describe the generation of chicken DT40 B cells, in which the FAN1 locus was disrupted by gene targeting. FAN1-null cells are highly sensitive to cisplatin and MMC, but not to ionizing or UV radiation, methyl methanesulfonate, or camptothecin. The cells do not display elevated sister chromatid exchange frequency, either sporadic or MMC-induced. Interestingly, MMC treatment causes chromosomal instability that is quantitatively, but not qualitatively, comparable to that seen in FA cells. This finding, coupled with evidence showing that DT40 cells deficient in both FAN1 and FANCC, or FAN1 and FANCJ, exhibited increased sensitivity to cisplatin compared with cells lacking only FAN1, suggests that, despite its association with FANC2/FANCI, FAN1 in DT40 cells participates in the processes of damage induced by interstrand cross-linking-generating agents also independently of the classical FA pathway.

Results

Avian FAN1 Is a Nuclease. To test whether chicken FAN1 is indeed a nuclease as predicted by bioinformatic analysis (4, 5) and whether it shares its substrate specificity with the human polypeptide, we expressed in SF9 cells the wild-type chicken protein as well as a mutant carrying an aspartate-to-alanine substitution (D977A) in the putative nuclease active site (Fig. S1A). Incubation of the untreated purified polypeptides (Fig. S1B) with ΦX174 DNA, single-stranded circular substrate that contains numerous secondary structures (hairpin loops and bulges) susceptible to cleavage by most structure-specific endonucleases in vitro, resulted in extensive degradation of the DNA by the wild-type enzyme but not by the D977A mutant (Fig. S1C). As the latter protein was able to bind DNA in a gel-shift assay with an affinity similar to the wild-type protein (Fig. S1D), we concluded that its inactivity was linked to the mutation of the active site, rather than to misfolding. These tests unambiguously showed that...
avian FAN1 is an endonuclease. By incubating the enzyme with a variety of oligonucleotide substrates, we could confirm that, like the human protein (7–10), the avian enzyme displays preference for the 5′-flap structure, even though other branched substrates were also cleaved, albeit less efficiently (Fig. 1). Interestingly, incubation of FAN1 with the 5′-labeled 3′ flap and three-way junction substrates, which were poorly addressed by the endonuclease as witnessed by the absence of an ~30-mer product band, gave rise instead to rapidly migrating labeled species that we attributed to 1- to 4-nucleotide-long fragments. This shows that FAN1 also possesses a 5′→3′ exonuclease activity that prefers double-stranded DNA ends (Fig. 1, left set). We could confirm this prediction by labeling the bottom 60-mer strands at their 3′ termini. Incubation with FAN1 gave rise in all cases to degradation products, the smallest of which were ~30 nucleotides long, which most likely resulted from a 5′→3′ degradation of the double-stranded regions of the substrates up to the junction where the strands separate (Fig. 1, right set).

**Disruption of the DT40 FAN1 Locus Does Not Affect Cell Growth.** The chicken gene encodes a polypeptide of 1,034 amino acids (Fig. S1A) that displays 52% similarity and 65% identity at the amino acid level to its human 1,017-residue ortholog. Targeting constructs were generated which lacked parts of exons 2 and 3 (Fig. S2A) encoding the putative UBZ domain. Disruption of the FANI locus was confirmed by Southern blot (Fig. S2B) and RT-PCR (Fig. S2C) analyses. The FAN1−/− and wild-type DT40 cells displayed similar doubling times (Fig. S2D) and very similar cell-cycle profiles (Fig. S2E). Thus, FAN1 disruption does not affect the basal growth properties of DT40 cells.

**Disruption of the FAN1 Locus Sensitizes DT40 Cells to ICL-Generating Agents.** We then measured the sensitivity of the FAN1−/− DT40 cells to a range of DNA-damaging agents. DT40 wild-type and two independent clones of FAN1−/− cells showed similar sensitivities to γ-rays, UV, methyl methanesulfonate (MMS) (Fig. S2F–H), and camptothecin (Fig. 2A). In contrast, FAN1−/− cells were more sensitive to cisplatin or MMC than wild-type DT40 cells (Fig. 2B and C). The hypersensitivity to the latter reagents could be rescued by a stable transfection of FAN1+/+ clone 1 with a vector carrying chicken wild-type FAN1 cDNA (GdFAN1) (Fig. 2B and C). These results also agree with those obtained by siRNA-mediated knockdown of FAN1 in human cells (7–10). In contrast, the knockout cells could not be rescued by the expression FAN1 cDNA carrying a D977A substitution in the nuclease domain (Fig. S2F). Taken together, these data show that the observed hypersensitivity to ICL-inducing agents was caused solely by disruption of the FAN1 gene and that the nuclease domain is essential for the function of this protein.

**FAN1 Deficiency Leads to Chromosomal Instability.** Hypersensitivity to ICL-inducing agents is a common phenotypic trait of FA cells, as is chromosomal instability, both spontaneous and damage-induced (12). We therefore studied sister chromatid exchange (SCE) frequencies in FAN1−/− DT40 cells. As shown in Fig. 3A, only very small increases in spontaneous and MMC-induced SCEs were seen in the FAN1−/− cells compared with the wild-type DT40 control. However, a very different picture emerged when we compared chromosomal aberrations in these two cell lines after MMC treatment. The number of chromosomal changes increased notably (Fig. 3B), and whereas disruption of the FAN1 locus had little effect on spontaneous aberrations, the number of induced chromosomal changes was approximately 10-fold higher in the FAN1−/− cells compared with the wild-type control.

**Fig. 1.** *Gallus FAN1* is an endonuclease. FAN1 cleaves preferentially 5′-flaps. The wild-type (WT) enzyme or the D977A (DA) mutant was incubated with a series of oligonucleotide substrates shown below the panel. The arrow indicates the preferred cleavage product. The rapidly migrating radioactive species seen at the bottom of this 20% denaturing polyacrylamide gel correspond to DNA fragments 1–4 nucleotides in length. The position of the radiolabel is indicated by an asterisk. M, marker; 3-WJ: three-way junction.

**Fig. 2.** FAN1-deficient DT40 cells are hypersensitive to DNA cross-linking agents. DT40 cells of the indicated genotypes were exposed to γ-rays, UV, MMS (Fig. S2F–H), and camptothecin (A), cisplatin (B), and mitomycin C (C). The doses of the agents are shown on the x axes on a linear scale, whereas the fractions of surviving colonies are displayed on the y axis on a logarithmic scale. Each data point represents an average of at least three independent experiments ±SD. #1 and #2, two independent FAN1 knockout clones. FAN1+/GdFAN1 denotes a FAN1 knockout clone stably transfected with an expression vector encoding a FAN1 ORF. As shown, expression of this protein rescued the hypersensitive phenotype of the FAN1 knockout cells.

**Fig. 3.** FAN1-deficient cells display an increased rate of chromosomal aberrations. (A) Sister chromatid exchange frequencies in wild-type and FAN1−/− DT40 cells, either untreated or treated with 20 ng/mL MMC. The graph shows the number of metaphases (y axis) containing a given number of SCEs (x axis). The mean number of SCEs is indicated. At least 50 metaphase spreads were counted for each experiment and the graph shows the mean number of SCEs. (B) Occurrence of chromosomal aberrations in wild-type, FAN1−/−, FANC−/−, and FANC−/− FAN1−/− DT40 cells, either untreated or treated with the indicated doses of MMC.
threefold higher than in wild-type cells upon treatment with 20 ng/mL MMC. Under identical conditions, cells disrupted in the FANCC and FANCJ loci displayed higher numbers of spontaneous aberrations than FAN1−/− cells, as well as a greater number and variety of aberrations after MMC treatment (Fig. 3B). Thus, whereas the changes observed in the wild-type and FAN1-deficient cells were exclusively chromosomal breaks and gaps, FANCC−/− and FANCJ−/− cells displayed in addition chromatid aberrations, as could be expected from their increased SCE frequencies (Fig. 3B) (13–15).

In contrast to FANCC−/− cells, which displayed a lower frequency of gene targeting than wild-type DT40 cells (Fig. S3A) (13), gene-targeting frequencies measured at two different loci in FAN1−/− cells were similar to those observed in the wild-type controls (Fig. S3A). In addition, no change in the efficiency of homologous recombination for FAN1-deficient cells was detected in a reporter assay which scores for neomycin resistance following the recombination between two disrupted neomycin ORFs integrated in DT40 genomic DNA that is triggered by the induction of a sequence-specific double-strand break in one of the neomycin inserts (Fig. S3B) (16). These results imply that FAN1 is not involved in the control of homologous recombination in DT40 cells.

**FA and FAN1 Deficiencies Are Additive Rather Than Epistatic.** Although lack of FAN1 or FA proteins leads in both cases to hypersensitivity to cisplatin and MMC, the differences in the subtypes of chromosomal aberrations described above suggested that the enzymes might not process identical lesions or intermediates generated by these agents. To test this prediction, we generated double mutant DT40 cells. The FAN1−/−/FANCC−/− double knockout cells grew more slowly than wild-type DT40 cells, but at the same rate as FANCC−/− cells (Fig. S4A). Importantly, they displayed higher sensitivity to cisplatin than either single mutant (Fig. 4A), and the number of MMC-induced chromatid aberrations was also higher than in the single mutants (Fig. 4B). However, the number of spontaneous SCEs in the double knockout cells was not greater than in the FANCC−/− line (Fig. 4E Left). Similarly to the FANCC−/− cells, the FANCI−/−/FANCC−/− knockout cell line also proliferated with slower growth kinetics than wild-type DT40 or FAN1−/− cells, and FAN1 inactivation reduced their growth rate even further (Fig. S4B). Expression of wild-type FAN1 in these cells reverted the growth defect back to the level seen in FANCI−/− cells, which showed that the difference was indeed due to the disruption of the FAN1 locus. Like the FAN1−/−/FANCC−/− clones, the FAN1−/−/FANCI−/− cells were also more sensitive to cisplatin than either of the single knockouts (Fig. 4C) and the number of MMC-induced chromatid aberrations was likewise increased (Fig. 4D). As in the case of FANCC, SCE frequency in FAN1−/−/FANCI−/− cells was similar to that seen in FANCC−/− cells (Fig. 4E Right). This further confirmed our hypothesis that although FAN1 is clearly involved in the cellular response to ICL-inducing agents, it does not appear to be involved in the processing of spontaneous DNA damage together with FA proteins.

**FAN1 Deficiency Does Not Affect Ubiquitylation of FANCD2.** Cells lacking constituent proteins of the FA core complex fail to monoubiquitylate the FANCD2/FANCI heterodimer upon treatment with DNA-damaging agents (11). As shown in Fig. 5, MMC-induced FANCD2 monoubiquitylation in FAN1−/− and in wild-type DT40 cells was similar, in contrast to FANCC−/− cells. FAN1 is therefore not required for the activation of the ubiquitin ligase of the FA core complex. This resembles the situation in FANCJ-deficient cells (Fig. 5), and could indicate that FAN1, like FANCJ, participates in DNA damage processing downstream of the FA complex. An alternative explanation might be that FAN1 might not be directly linked to the FA pathway, as implied by the data presented above.
FAN1 Targeting to DNA Damage Foci Is Dependent on the FA Complex. Treatment of cells with DNA-damaging agents frequently leads to the accumulation of DNA damage response proteins in sub-nuclear foci at (or close to) the sites of damage. To find out whether FAN1 behaved similarly, we transfected DT40 cells with a vector expressing a GFP-FAN1 fusion protein. As shown in Fig. S5A, the untreated transfected cells contained a small number of nuclear foci, which might represent spontaneous DNA damage, possibly stalled replication forks. In contrast, in MMC-treated cells, the number of these foci increased substantially. Because MMC is known to induce foci containing the FA factors, we wanted to test whether the FAN1 foci colocalized with those formed by FANCD2, which, together with its heterodimeric partner FANCI, is believed to be responsible for the recruitment of repair proteins to blocked replication forks and other types of DNA damage. That FANCD2 and GFP-FAN1 almost completely colocalized (Fig. S5A and B) was somewhat unexpected, based on the results of the experiments described above. Even more surprising was the fact that, like FANCD2, GFP-FAN1 failed to form MMC-induced foci when expressed in FANCC-deficient cells. These results indicate that FAN1 and FANCD2 are targeted to the same foci, and that this targeting depends on a functional FA complex. However, as the ubiquitylation of FANCD2 was not affected by FAN1 deficiency (Fig. 5), FAN1 appears to act downstream of FANCD2 (7–10).

Discussion

The data presented in this study confirm and extend our findings in the human system, which showed that FAN1 is a DNA repair enzyme that participates in the processing of lesions formed by ICL-generating compounds (7–10).

Hypersensitivity of FA cells to ICL-inducing agents is a clinical hallmark of Fanconi anemia. However, the slower growth and spontaneous chromosomal instability of FA cells imply that the pathway evolved to deal with endogenous damage, such as DNA adducts arising through reactions with lipid peroxidation by-products, or complex secondary structures that hinder replication, such as hairpins that might arise in regions of dyad symmetry or in triplet repeats (17, 18) and that can give rise to chromosomal instability if uncorrected. These lesions are apparently not addressed by FAN1, given that cells lacking this protein divide with similar kinetics to wild-type DT40 cells (Fig. S2D) and display normal spontaneous SCE frequency (Fig. 3f). Further evidence in support of this hypothesis came from the findings that disruption of the FAN1 locus in FANCC<sup>−/−</sup> or FANCI<sup>−/−</sup> cells gave rise to no significant increase in the frequency of SCEs (Fig. 4e). These aberrations are believed to arise through reciprocal exchange of genetic material, where Holliday junctions generated by homologous recombination at arrested or blocked replication forks are resolved to yield cross-over products. Such a situation is prevented primarily by the BLM/Top3α/RMI1 complex and, consequently, BLM-deficient cells exhibit high SCE frequencies. The recruitment of the latter complex to replication forks was recently reported to be mediated (at least in part) by the FANCN protein (19), and this might explain why defects in the FA pathway give rise to SCEs. This evidence might also imply that FAN1 is not recruited or required at these spontaneous replication blocks.

On the other hand, FAN1 is recruited to foci induced by ICL-generating agents, where it most likely acts in the cleavage of cross-linked DNA molecules. It is interesting to note that the 5′-flap preference of FAN1 complements the 3′-flap selectivity of MUS81/EME1 or XPF/ERCC1 (20–22), the damage induced by cross-linking agents in chicken cells appears to be channeled into different pathways, some of which involve the FA complex and others not. Although this scenario might appear unlikely due to the high degree of evolutionary conservation of the FA pathway in higher eukaryotes, the FAN1 nuclease motif evolved earlier, as its homologs are found already in Schizosaccharomyces pombe and Pseudomonas aeruginosa. The latter proteins contain the endonuclease domain but not the zinc-finger motif that is required for interaction with FANCJ (8); it will therefore be interesting to learn whether these FAN1 homologs are involved in ICL processing in these unicellular organisms.

Fanconi anemia is a rare genetic disease characterized by congenital defects, bone marrow failure, chromosomal instability, and cancer susceptibility (11). Given that untreated FAN1-deficient cells do not display proliferation defects, the likelihood that individuals with inactivating mutations in FAN1 will present with an FA-like syndrome may be low. It is also possible that FAN1 is functionally at least partially redundant with other, as yet unidentified, nucleases. Functional redundancy might help explain why genes encoding XPF/ERCC1 or MUS81/EME1 (20–22) have not been found mutated in FA patients. However, it is likely that FAN1 will turn out to be clinically important, as its loss clearly sensitizes cells to ICL-generating drugs. Given that MMC and especially the platinum compounds cisplatin, oxaliplatin, and carboplatin are in increasing use in the therapy of a broad range of cancers (23, 24), elucidation of the biological role of this enzyme in the metabolism of ICLs is of substantial clinical importance. By generating multiple knockout lines, the DT40 system should allow us to dissect ICL processing further, and thus provide us with insights into this important pathway of DNA metabolism.

Methods

Accession codes, cDNA, protein purification, and standard procedures are described in SI Text.

Specific Nuclease Assay. One nanomole of labeled substrate was incubated with 10 nmol of FAN1 wild-type or D977A mutant in 25 mM Hepes KOH (pH 7.4), 25 mM KCl, 1 mM MgCl2 as indicated, and 0.05 mg/mL BSA for 30 min at 37 °C. The reaction was terminated with 0.1% SDS, 14 mM EDTA, and 30 mM KOH.
0.1 mg/mL proteinase K and incubation at 55 °C for 15 min. Loading buffer was added and the samples were denatured and separated on a 20% de-
naturing polyacrylamide gel for 1 h at 40 V/cm. The gels were dried and the bands were visualized on a PhosphorImager (Typhoon 9400; GE Healthcare).

**Proliferation Analysis and Sensitivity Assay.** The experimental methods for proliferation analysis and sensitivity assays were performed as described previously (16). To measure the sensitivity of DT40 double knockout FAN1/FANCC and FAN1/FANCIJ cells, cells were cultured in medium containing cis-
platin. The experimental methods for cell counting and cycle-cell analysis were described previously (16).

**Chromosomal Aberration Analysis.** Preparation of chromosome spreads and karyotype analysis were performed as described previously (25). To measure mitomycin C-induced chromosomal aberrations, cells were incubated with 2.5, 5, 10, and 20 ng/mL mitomycin C for 24 h before harvest and fixation. Cells were incubated with colcemid (final concentration, 0.1 μg/mL) for the last 2 h to enrich for mitotic cells.

**ACKNOWLEDGMENTS.** The authors thank Drs. H. Arakawa (Max Planck Institute, Martinsried, Germany) and J. M. Buerstedde (Genome Damage and Stability Centre, Brighton, UK) for generous gifts of DT40 strains and vectors. This work was supported by Swiss National Science Foundation Grant 3100A0-118158 to J.J.
Supporting Information

Yoshikiyo et al. 10.1073/pnas.1011081107

SI Text

Accession Codes. *Gallus gallus* XP_413768.2; *Homo sapiens* EAW61257.1; *Mus musculus* Q692T1.2; *Rattus norvegicus* XP_001058546.1.

cDNA of *Gallus FAN1*. The 3.2-kb chicken *FAN1* cDNA was amplified from a DT40 cDNA library using the primer pair 5'-GCC GCG GAA AGG CTT TGA AGT TCC-3' and 5'-CTG GTA GCG TGT AGC ATG ATG TCC-3' and cloned into different vectors.

Oligonucleotide Sequences. f7: 5'-ATT GAC TAG GTT ACA TGA CTG AAT GAT AGT-3'; f8: 5'-GGG GAA AGG CTT TGA AGT TCC-3'; f9: 5'-ACT ATT CAG TCA TGT AAC CTA GTC AAT CTG CGA GCT CGA-3'; f10: 5'-GAG GTC ACT CCA GTG AAT TCG AGC TCG CAG TCA ATG TCG ACA TCA TGA GTC TCT TAC TCC-3'.

DNA Substrates for Nuclease Assays. Oligonucleotides were purchased from Microsynth and 5'-labeled with polynucleotide kinase and [γ-32P]ATP or 3'-labeled with TdT and [α-32P]dCTP. The substrates were annealed in 25 mM Hepes-KOH (pH 7.6) and 50 mM KCl by heating for 5 min at 95 °C and slow cooling to RT. The following oligonucleotides were used to generate: splayed arm: f9 and f10; 3'-labeled arm: f9, f10, and f17; 5'-labeled arm: f9, f10, and f8; three-way junction: f9, f10, f7, and f8.

FAN1 Expression and Purification. The cDNA of chicken FAN1 wild-type and D977A mutant was cloned into a modified pFastBac1 vector that contains an N-terminal maltose binding protein (MBP) tag (a kind gift of Petr Cejka, University of California, Davis, CA) (1). Sf9 virus was generated and insect cells were transfected following the user manual (Gibco-BRL). Sf9 cells expressing FAN1 were harvested 72 h postinfection by centrifugation, washed once in PBS, and snap frozen.

For purification, the pellet was resuspended in maltose column buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM EDTA) containing 1 mM PMSF and a proteinase inhibitor mixture (Roche), chilled on ice for 20 min, and sonicated. After centrifugation (18,000 × g, 1 h, 4 °C), the supernatant was incubated with amylose resin (New England BioLabs). Subsequently, the column was washed with maltose column buffer and MBP-FAN1 was eluted (elution buffer: 20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM EDTA, 10 mM maltose). Fractions containing MBP-FAN1 were pooled and subjected to a PreScission Protease (GE Healthcare) digest to remove the MBP tag. The digest took place in PreScission buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM DTT; 0.01% Nonidet P-40) for 4 h at 4 °C on a rotor at 300 rpm. After the digest was terminated, the suspension was loaded onto a heparin column (GE Healthcare), the column was washed (wash buffer: 25 mM Hepes-KOH, pH 7.6, 150 mM KCl, 10% glycerol, 1 mM EDTA, 1 mM DTT), and FAN1 was eluted in buffer containing 25 mM Hepes-KOH (pH 7.6), 10% glycerol, 1 mM EDTA, and 1 mM DTT with a salt gradient of 15–100% KCl. Fractions containing the purified, tag-free FAN1 were pooled, snap frozen, and stored at −80 °C.

Band-Shift Assays. Purified FAN1 wild-type and the D977A mutant (0.3–10 pmol) were incubated with 1 pmol fluorescein-labeled double-stranded DNA substrate (38-mer) for 5 min at RT in 50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, and 5% glycerol. Increasing amounts of poly(dIC)-d(IC) (6–60 ng/μL) were used as nonspecific competitor in reactions containing 10 pmol protein. Samples were loaded onto a 1% agarose gel and visualized using a PhosphorImager (Typhoon 9400; GE Healthcare).

ΦX174 Non specific Endonuclease Assay. ΦX174 was incubated with increasing amounts of wild-type FAN1 or with its ΔD977A catalytic site mutant in endonuclease buffer (25 mM Hepes-KOH, pH 7.4, 25 mM KCl, 0.05 mg/mL BSA) for 1 h at 37 °C. The reaction was stopped by addition of 0.1% SDS, 14 mM EDTA, and 0.1 mg/mL proteinase K and incubation at 55 °C for 15 min. Ten percent glycerol was added and the DNA species were separated on a 0.8% agarose gel for 45 min at 80 V. EcoExoIII, exonuclease III of *Escherichia coli*, served as the positive control for degradation of the DNA, whereas the restriction enzymes HhaI and HinII cut the ΦX174 DNA at double-stranded hairpins containing their respective restriction sites. The restriction enzyme MboI served as the negative control, as none of the secondary structures arising in folded ΦX174 DNA reconstitute its recognition sequence.

Construction of Gene-Targeting Vectors. Specific regions of the genomic *Gallus FAN1* were PCR-amplified using the primers 5'-GGG CTC CAG GAG GGT GTT GCG AGC AGT GTT GGA GAA TTT CAA GCT G-3' and 5'-GGG GGA TCC GCA TGG GAC ATC CCA CCA CCG CCG CCG GTG CAG CAG GAG GAC GATC CCA CCA CCG CCG CCG GGT TCT CTC TCC TGA TCC-3' (left arm of the targeting construct), as well as 5'-GGG GGT CCC CTT CAG CAG GAA TCC ACA GATG CTC TCC TCA GAC ATG CAT TCA GAC AGT TCC-3' (right arm of the targeting construct). Amplified 4.2-kb left and 3.6-kb right arms were cloned into the pCR2.1-TOPO vector (Invitrogen). The 4.2-kb left and 3.6-kb right arms were then sequentially subcloned into the XhoI-BamHI and BamHI–NotI sites of pBlueScript SK (+) vector, respectively. The *puro* and *bsr* selection marker genes flanked by loxp sequences were inserted into the BamHI site of the vector to generate the *FAN1-puro* and *FAN1-bsr* disruption constructs. The 480-bp fragment generated by PCR amplification of genomic DNA using the primers 5'-CCC TCA GAG AAG AAG TCT GAA TTTCAA GCT G-3' and 5'-GGG GGA TGT AGC ATG GTC GAC CAG GAC GGT TAA TCC-3' was used as a probe for Southern blot analysis to screen for gene-targeting events. Gene disruption constructs were linearized with NotI before transfection into DT40 cells.

Generation of FAN1-Deficient DT40 Cells. Wild-type DT40 cells were sequentially transfected with *FAN1-puro* - and *FAN1-bsr*-targeting constructs to obtain *FAN1−/−* cells. Gene-targeting events were verified by the appearance of a 4.2-kb DNA fragment and the disappearance of an 11-kb fragment in Southern blot analysis of Sp6-digested genomic DNA. Gene disruption was confirmed by RT-PCR analysis using the primers 5'-CCC TCA GAG AAG AAG TCT GAA TTTCAA GCT G-3' and 5'-CTG ATA GGA TTTCAA GCT GAC ATC GAG TAT GCC C-3' under the following condition: 25 cycles of 98 °C for 30 s, 56 °C for 30 s, and 72 °C for 60 s. As a positive control for the RT-PCR analysis, β-actin transcripts were analyzed using the primers 5'-AGG TAT CCT GAC CCT GAA GTA CC-3' and 5'-CAT GGC TGG GGT GTT GAA GGT CTC-3'. For reconstitution experiments, wild-type cDNA and the C60A or D977A variants were inserted into the p176 expression vector containing a GFP expression
cassette downstream from an internal ribosome entry site IRES-GFP. The expression plasmid was linearized with PvuI before transfection into DT40 cells. The conditions for DNA transfections, cell culture, and selection were described previously (2).

**Cell Survival Assays.** Cell sensitivity to genotoxic agents was measured by clonogenic assays as described in Methods and in ref. 2. The rescue experiments shown in Fig. S2I were carried out using an assay based on the estimation of ATP in extracts of treated and untreated cells grown in liquid culture. Briefly, 1 × 10⁶ DT40 cells were incubated in 1 mL culture medium per well containing the indicated cisplatin concentrations. After 72 h, the cells were lysed and the amount of ATP in the extracts was measured using the CellTiter-Glo Kit (Promega) according to the manufacturer’s instructions (3). At least three independent experiments were carried out with three different clones.

**Sister Chromatid Exchange Frequency.** Measurement of sister chromatid exchange (SCE) levels was carried out as described previously (4). To measure mitomycin C-induced SCEs, cells were labeled with BrdU for two cell-cycle periods (16 h) and treated with 2.5, 5, 10, and 20 ng/mL mitomycin C for 8 h. The cells were then incubated with colcemid (final concentration, 0.1 μg/mL) to enrich for metaphase cells for the last 3 h before harvesting. Fixation and preparation of chromosome spreads were described previously (4).

**Targeted Integration Frequency Measurement.** Homologous recombination was evaluated by assaying targeted integration events at the OVALBUMIN and CENP-H loci. Each disruption construct was transfected into cells as described previously (4). Gene-targeting events were identified by Southern blotting.

**Homologous Recombination-Mediated Repair of I-SCEI–Induced Double-Strand Breaks.** Analysis of homologous recombination-mediated repair of artificially induced double-strand breaks in a reporter assay was carried out as described previously (2). The SCneo construct was targeted into the OVALBUMIN locus in wild-type-, FAN1-, FANCC-, and FANCJ-deficient DT40 cells. I-SCEI expression vector was transiently transfected into the cells, which were subsequently selected for neomycin resistance.

**FANCD2 Monoubiquitylation Analysis.** FANCD2 monoubiquitylation was induced with 500 ng/mL mitomycin C (MMC) for 6 h before harvesting the cells. Detection was described previously (5).

Fig. S1. Analyses of Gallus FAN1 expressed in Sf9 insect cells. (A) Evolutionarily conserved domains of FAN1. Gallus FAN1 is a polypeptide of 1,034 amino acids with a predicted N-terminal CCHC zinc-finger motif and a C-terminal PD-(D/E)XXK nuclease domain. Identical amino acid residues are in black boxes and similar ones are in gray. The key residues of the zinc-finger and endonuclease domains are designated with horizontal lines. The asterisk denotes the catalytic aspartate 977 mutated in the DA variant. (B) Expression and purification of FAN1 from Sf9 cells. Sf9 noninf., Sf9 cell extract prior to infection; Sf9 inf., Sf9 cell extract expressing FAN1; enrich. Amylose resin, FAN1 enriched over amylose resin. PreScission (digest) (GE Healthcare) shows FAN1 (upper band, arrow) and removed MBP tag (lower band, arrow). WT, FAN1 wild-type; D977A, FAN1 endonuclease mutant D977A purified over HP-Sepharose column (GE Healthcare). Ten percent SDS gel stained with Coomassie blue. (C) The single-stranded viral DNA of \( \Phi X174 \) contains several hairpin loops that are cleaved by the restriction nucleases HhaI and HinfI, but not by MboI. Other secondary-structure features are cleaved by structure-specific endonucleases. When \( \Phi X174 \) DNA was incubated with \( E. coli \) exonuclease III (ExoIII) or increasing amounts of wild-type FAN1 (WT), the substrate DNA was degraded. No significant degradation was observed upon incubation with the D977A mutant. This indicates that FAN1 is indeed an endonuclease and that aspartate 977 is one of the principal catalytic residues of this enzyme. M, marker. The figure is a negative image of an 0.8% agarose gel stained with SYBR gold. (D) FAN1 D977A mutant is able to bind to dsDNA. Addition of competitor dIdC abolishes the interaction. The figure is a negative image of an 0.8% agarose gel.
Fig. S2. Generation and characterization of a FAN1-deficient DT40 cell line. (A) Schematic representation showing a part of the FAN1 locus and the targeting constructs. The filled boxes represent exons. The thick lines show the genomic regions amplified for targeting vector arms. The probe for Southern blot analysis and the primers used for RT-PCR (small arrows) are indicated. SphI restriction digest was used for screens for targeted integration events. (B) Southern blot analysis of SphI-digested genomic DNA using the probe indicated in A. (C) RT-PCR analysis of total RNA isolated from FAN1−/− cells, using the primers shown in A. The coding region of the chicken β-actin gene was amplified as a control. (D) Doubling times of FAN1−/− and wild-type DT40 cells are similar. (E) Cell-cycle progression and distribution of FAN1−/− and wild-type DT40 cells are similar. (F–H) Clonogenic cell survival assays. DT40 cells of the indicated genotypes were exposed to γ-rays (F), UV (G), and methyl methanesulfonate (MMS) (H). The doses of the agents are shown on the x axes on a linear scale, whereas the fractions of surviving colonies are displayed on the y axis on a logarithmic scale. Each data point represents an average of at least three independent experiments ±SD. #1 and #2, two independent FAN1 knockout clones. (I) Cell survival assay demonstrating that the cisplatin-sensitive phenotype of FAN1−/− knockout cells could be rescued by expression of wild-type FAN1 but not its variant carrying the D977A substitution in the nuclease active site.
Fig. S3. Gene-targeting efficiency and homologous recombination-mediated repair in wild-type, \textit{FAN1}^{-/-}, \textit{FANCC}^{-/-}, and \textit{FANCJ}^{-/-} DT40 cells. (A) Gene-targeting efficiency in wild-type, \textit{FANCC}^{-/-}, and \textit{FAN1}^{-/-} DT40 cells. The result shows that FAN1 deficiency does not affect the efficiency of targeted integration. (B) Analysis of homologous recombination-mediated repair of artificially induced double-strand breaks in a plasmid-based reporter assay in wild-type, \textit{FAN1}^{-/-}, \textit{FANCC}^{-/-}, and \textit{FANCJ}^{-/-} DT40 cells. Each data point represents an average of at least three independent experiments ±SD. We engineered DT40 cells carrying the S2neo vector in the OVALBUMIN locus. This vector encodes a neomycin resistance cassette disrupted at its 3' end by a stop codon and a recognition site for I-SceI endonuclease. Transient expression of I-SceI generates a double-strand break in the S2neo construct, which triggers homologous recombination between the 3' neo fragment located upstream of the S2neo vector. This reconstitutes a functional neomycin resistance cassette. The frequency of homologous recombination can then be estimated by counting the fraction of G418-resistant cells. The results show that FAN1 deficiency does not affect double-strand-break–induced homologous recombination.

Fig. S4. Doubling times of different knockout DT40 cell lines. (A) The doubling time of \textit{FANCC}^{-/-} cells is slower than that of wild-type DT40 cells, but is similar to that of the \textit{FAN1}^{-/-}/\textit{FANCC}^{-/-} double mutant. (B) Doubling time of \textit{FAN1}^{-/-}/\textit{FANCJ}^{-/-} DT40 cells is slower compared with wild-type, \textit{FAN1}^{-/-}, \textit{FANCJ}^{-/-}, and \textit{FAN1}^{-/-}/\textit{FANCJ}^{-/-}/\textit{GdFAN1} (FAN1 rescue) cells.
**Fig. S5.** Dependence of subcellular localization of FAN1 and FANCD2 on FANCC. (A) FANCD2 and FAN1 colocalize in both spontaneous (−MMC) and MMC-induced (+MMC) subnuclear foci in wild-type but not FANCC/− cells. (B) Quantification of A; at least 200 cells were counted in each field.